Navigation Links
Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
Date:4/9/2008

ATLANTA, April 9, 2008 /PRNewswire-USNewswire/ -- Dutch biotechnology company Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative (SATVI) present a progress update and immunology data from a Phase I Ad35 tuberculosis vaccine study at the biennial "Tuberculosis Vaccines for the World" conference (Atlanta, Georgia, April 9 to 11) today. The study, conducted in Worcester, South Africa and launched in May 2007, is the second phase I study in a current series of three and has revealed promising results.

Highest CD8 immune responses ever in a TB vaccine study

Preliminary data show both critical arms of the cellular immune system, CD4 and CD8 immune T-cells were induced and that in those participants who responded, CD8 immune responses are considerably higher than has ever previously been seen in a TB vaccine study.

The trial of AERAS-402/Crucell Ad35, which began in May 2007, is being conducted as a double-blind, randomized, placebo-controlled dose escalation study in four groups of healthy adults vaccinated at birth with BCG (Bacille Calmette-Guerin) vaccine. A total of 40 healthy adult volunteers are enrolled.

"While preliminary, these results are promising. We are pleased that Crucell's technologies are playing a key role in the search and development of a much-needed TB vaccine," said Dr. Jaap Goudsmit, Chief Scientific Officer at Crucell. "We highly value the collaboration with Aeras and SATVI on this important mission."

Third key clinical phase I study in progress

Aeras and Crucell began jointly developing this vaccine candidate in 2004 using Crucell's AdVac(R) vaccine technology and PER.C6(R) manufacturing technology. A first Phase I clinical trial launched in October 2006 in Kansas, USA indicated that the vaccine candidate is safe in healthy adults in the US. The results of a second study, launched in May 2007, are presented in Atlanta at the "TB
'/>"/>

SOURCE Aeras Global TB Vaccine Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
2. Artists for a New South Africa Will be Shaking The Blues at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb Mo, Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles
3. Grammy Winner Marc Cohn to Perform for African AIDS Organization at Carolina HopeFest
4. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
5. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
6. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
7. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
8. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
9. Tampax and Always Launch Protecting Futures Program Dedicated to Helping African Girls Stay in School
10. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
11. Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... WHITEHOUSE STATION, N.J. , Sept. 19, 2014 Merck ... the United States and Canada , ... on Desafiando La Diabetes: Logra Tus Metas , an educational ... of their blood sugar -- a key treatment goal to help ... the United States are at a higher risk for ...
(Date:9/19/2014)... 19, 2014 UBM Medica US announces that  ... community to help oncologists and other clinicians gain a ... use of targeted therapies and immunotherapies, discusses some of ... Every September, Blood Cancer Awareness ... awareness about blood cancers—helping to increase survival rates and ...
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
(Date:9/19/2014)... September 19, 2014 Unbound , an ... families in regions of the Philippines being affected by both ... than 1,060 families evacuated to the nearest public schools while ... heavy rain and gusty winds to portions of the northern ... flooding. Some homes filled with more than 10 feet of ...
(Date:9/19/2014)... cancers have abnormally upregulated chemical signals related to ... during tumor formation is not fully understood. , ... both researchers in the department of Pathology and ... University of Pennsylvania, and colleagues report that TIPE3, ... targeting these pathways. , Lipid second messengers play ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 According to ... of the embattled blood-thinner Xarelto, named as defendants in ... Common Pleas, have moved the court to dismiss those ... not have sufficient connection with Philadelphia.* The cases include, ... al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), which ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... 19, 2014 The Alliance for ... with the National Fire Protection Association (NFPA), a ... formalized today in a Memorandum of Understanding signed ... workers and other stakeholders with information, guidance and ... the health and safety of workers in ready-made ...
Breaking Medicine News(10 mins):Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:New cancer drug target involving lipid chemical messengers 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3
... , FRIDAY, Aug. 12 (HealthDay News) -- Religious ... facing hardship or conflict, a new study indicates. ... such link. Not only are fewer people religious ... in regions where there,s hardship and strife, regardless of ...
... HealthDay Reporter , THURSDAY, Aug. 11 (HealthDay News) -- Depressed ... suggests. "We know that stroke can increase risk of ... said study author An Pan, a research scientist at the ... associated with hormonal changes in the body and affects chemicals ...
... (HealthDay News) -- Obstructive sleep apnea (OSA) and sleepiness rapidly ... machines, a new study finds. CPAP is a common ... during sleep due to the repeated blockage of the upper ... stream of air through a mask or nose piece the ...
... of continuous positive airway pressure machines (CPAP) for patients ... the therapy is withdrawn, according to Swiss research. ... the American Thoracic Society,s American Journal of Respiratory ... obstructive sleep apnea who are established on CPAP treatment, ...
... in illness and recovery is a primary influence upon ... a first-of-its-kind study has discovered. Outreach and education efforts ... concerns and improve health care quality in this rapidly ... fasting occurring this month is but one of many ...
... Researchers from the Indiana University have identified common ... in Intensive Care Units (ICUs). The study, published ... and Hospital Epidemiology , the journal of the ... lessons learned from six ICUs as they implemented ...
Cached Medicine News:Health News:Religion Might Boost Happiness in Times of Stress 2Health News:Depressed Women Could Face Raised Risk of Stroke 2Health News:Depressed Women Could Face Raised Risk of Stroke 3Health News:Withdrawal of CPAP therapy results in rapid recurrence of OSA 2Health News:Religious beliefs shape health care attitudes among US Muslims 2Health News:Religious beliefs shape health care attitudes among US Muslims 3Health News:Common themes emerge in hospitals' anti-MRSA efforts: Study 2
... is a mechanical catheter intended to percutaneously ... access grafts. The disposable catheter requires no ... spiral shaft which extends beyond the 6F ... tip. In use, the tip spins to ...
... HYDROLYSER Percutaneous Thrombectomy Catheter is ... for rapid, effective and easy removal ... shunts. The HYDROLYSER catheter provides an ... thrombolytic therapy. ,Compatible with ...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system....
... The AVX catheter is designed to ... 12mm. High-pressure saline jets travel backwards ... to create a low pressure zone ... drawn into the catheter where it ...
Medicine Products: